image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Archived Events
UBS Global Healthcare Virtual Conference
May 25, 2021 at 4:00 PM EDT
View Webcast
RBC Capital Markets Global Healthcare Conference
May 18, 2021 at 1:20 PM EDT
View Webcast
20th Annual Needham Virtual Healthcare Conference
April 14, 2021 at 11:45 AM EDT
View Webcast
Corporate Presentations
Scientific Presentation
Print Page
Email Alerts
RSS Feeds
Contact IR